Login with Linked

Follow us on

Link Linkedin Youtube

Orserdu

Orserdu is a once-daily selective estrogen receptor degrader (SERD) approved for ER-positive, HER2-negative, ESR1-mutated, advanced or metastatic breast cancer in adults after endocrine therapy.

Molecule Details :

  • Molecule Name :

    Elacestrant

  • Innovator :

    STEMLINE THERAPEUTICS INC

  • Approval Date :

    27-Jan-23

  • NCE-1 Date :

    27-Jan-27

  • NCE Date :

    27-Jan-28

  • Dosage Form :

    Tablet

  • Strength :

    EQ 86MG BASE,EQ 345MG BASE

  • Therapeutic Category :

    Hormonal Therapy

  • Revenue ($M) :

    NA

Year-wise Projected Sales ($M) :

  • 2025 :

    6

  • 2026 :

    28

  • 2027 :

    58

  • 2028 :

    98

  • 2029 :

    139

  • 2030 :

    174

  • 2031 :

    212
Looking for this molecule for your next clinical research? Access regulatory-compliant comparators with assured timelines—delivered reliably through our global network.
Request a Quote

Why Choose Spring Bio Solution?

Supported 1000+ Clinical Trials globally

Provides services across regulatory, legal & clinical research

Unmatched intelligence on batches, expiry, spacing, and historical data from innovators

Integrated CRO Services as part of our offerings

Insights on global pricing for smarter clinical trial supply decisions 


Schedule a Call With Us
Login with Linked

Follow us on

Linkedin Youtube Link

Login NCE Grid

Register NCE Grid

Are you sure want to logout from NCE Grid?

Not Now
Logout
Need your comparator insight?